Hero Background


Accelerating and enabling your research interests

Partnering with Tempus provides access to an integrated multi-omic analytical platform and artificial intelligence capabilities designed to accelerate scientific discoveries.


Tempus offers a broad range of contract and traditional clinical options using our CAP-accredited CLIA-certified next-generation sequencing labs.

Tempus has additional capabilities including single-cell sequencing, genome-wide liquid biopsy profiling, spatial transcriptomics, methylation, genotyping and more.

Learn more about our sequencing capabilities
  • Tempus xT Targeted panel of 648 genes
  • Tempus xR Whole transcriptome RNA sequencing
  • Tempus xE Whole exome cancer assay
  • Tempus xF/xF+ Liquid biopsy panel of 105/523 genes

Tempus provides high-throughput solutions that deliver comprehensive datasets for a critical, integrated, and holistic understanding of your population. We offer a broad range of technologies to support research and development, including genotyping, methylation, NGS, and proteomics.

Learn more about our solutions
  1. Genotyping — A wide portfolio of genotyping solutions to support data projects of varying sizes.

  2. Methylation — Epigenetic & DNA methylation profiling from one of the highest-throughput methylation labs in the US.

  3. NGS — The full Illumina NGS suite of instruments to support all of your sequencing needs.

  4. Proteomics — Leading proteomic technologies with high-throughput capabilities, enabling precise biomarker discovery and expansive multi-omic analysis.

tempus ioTM

Our comprehensive immunotherapy platform provides sophisticated specimen analysis and data products, enabling our partners to assess key aspects of the tumor microenvironment (TME) and uncover vital genomic information that can be leveraged to optimize therapy response, identify novel biomarkers, and further stratify patient populations.

Learn more about our product
  • Tumor Mutational Burden (TMB)

  • Microsatellite Instability (MSI) Status

  • Gene Expression Target Profiling

  • Neoantigen Prediction

  • Human Leukocyte Antigen (HLA) Typing

  • HLA Loss of Heterozygosity (LOH)

  • Immune Infiltration

  • And more


Accelerating how researchers explore, evaluate, and design cutting-edge cancer treatments

At the Tempus|M modeling lab, a state of the art in-vitro facility, we use ex vivo tumor organoid biological modeling to understand the consequence of cancer genome alterations on growth, therapeutic sensitivity, and immune evasion.

Read the abstract

We leverage the genomic- and clinically-annotated organoid library through a suite of experimental capabilities on our customized platforms spanning high-throughput screening, high-content imaging, next-generation and single-cell sequencing, effector cell co-culture experiments, and standard histopathology capabilities. We work in close collaboration with our partners to offer a bespoke set of services in order to maximize value that may lead to further inquiry with other Tempus resources such as real-world and molecular data.

  • image description

    Organoid Development

    Using the Tempus xT assay on ex vivo tumors, Tempus correlates clinical patients’ responses with expanded real world cohorts, then further broadens these data sets with tumor organoids possessing somatic mutations or RNA expression signatures of interest to develop a model of universal concordance. Tempus organoid panels have the potential to validate hypotheses and observations from real world data; discover novel pathways and tumor drivers; and construct large scale data sets of in vitro sensitivities across hundreds of unique patients ex vivo for any given cancer, or target of interest.

  • image description

    Molecular Profiling

    Tumor organoids are characterized by the Tempus xT 648 gene-panel and whole transcriptome analysis including copy number prediction. An informatics pipeline is used to compare mutational recapitulation between the organoid models and the originating patient’s tumor. Organoids are also annotated for genome-wide analyses such as MSI and Homologous Recombination Deficiency (HRD).

  • image description

    Therapeutic Profiling

    Tumor organoids can be used to study established small molecules, antibody drug conjugates and effector cell systems such as CAR-T or CAR-NK. Tumor organoid response is evaluated with a robust and reproducible high content and machine learning based assay.


Advanced image recognition technology

Our highly-automated research image analysis is optimized around advanced pattern recognition and data characterization. The program is designed to quantify various tumor characteristics in a non-invasive and objective way. Our complex machine-learning algorithms are constantly running in the background, which allows us to improve the speed and accuracy of our insights engine in near real time.

Our web-based pathology and radiology platforms, combined with state-of-the-art image analysis tools, are designed to enable pathologists and researchers to access, share, and analyze images anywhere at any time for research purposes.

Request a Demo
image description

Clinical Trial and Research Offerings

At Tempus, our research partnership approach focuses on end to end solutions with the ability to customize deliverables and adapt projects to different sizes and budgets. We combine concierge service from our research operations team, scientific and medical expertise, multiple state of the art labs, and our continuously growing multimodal database, to deliver on research projects quickly and efficiently. We leverage our data & technology background to make your research usable and useful, with the goal of getting you from data to insights in minutes, not months.

Tempus TIME Trial® Program

Brings biomarker-driven clinical trials closer to patients across a just-in-time network of industry sponsors and providers with deep research expertise

Tempus generates, organizes, and analyzes extensive amounts of data to support providers in identifying relevant and actionable clinical trials for their patients. Our TIME Trial® Program enables providers in the network to have access to a portfolio of clinical trials and expand treatment options for their patients. All participants in the TIME Trial® Program utilize a pre-packaged clinical trial agreement, a pre-negotiated budget, a central IRB, and a team of dedicated Tempus research liaisons to help shorten trial start from months into weeks.

Learn more

This is data-driven precision medicine

This is the future of healthcare.